Hologic, Inc. (HOLX) EPS Estimated At $0.49

January 22, 2018 - By Peter Erickson

 Hologic, Inc. (HOLX) EPS Estimated At $0.49
Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.50, from 1.38 in 2017Q2. It dived, as 75 investors sold Hologic, Inc. shares while 145 reduced holdings. 64 funds opened positions while 129 raised stakes. 265.54 million shares or 0.74% less from 267.53 million shares in 2017Q2 were reported.
Dupont Cap Mgmt invested 0.13% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). Altfest L J And Incorporated holds 0.25% in Hologic, Inc. (NASDAQ:HOLX) or 13,820 shares. The New York-based Quantbot Techs Limited Partnership has invested 1.01% in Hologic, Inc. (NASDAQ:HOLX). Steinberg Glob Asset Mgmt invested 0.13% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). State Treasurer State Of Michigan holds 85,160 shares or 0.03% of its portfolio. Cipher L P has invested 0.33% in Hologic, Inc. (NASDAQ:HOLX). Aqr Mgmt Limited Liability Corp accumulated 311,490 shares. Reynders Mcveigh Cap Ltd Liability owns 182,124 shares or 0.87% of their US portfolio. Bessemer Gru invested in 1,945 shares. Brown Advisory invested in 0.01% or 111,410 shares. Moreover, Prudential has 0.04% invested in Hologic, Inc. (NASDAQ:HOLX) for 638,944 shares. Glenmede Company Na has 0% invested in Hologic, Inc. (NASDAQ:HOLX) for 5,335 shares. Boothbay Fund Mngmt Limited Liability Corp holds 8,651 shares or 0.05% of its portfolio. Curbstone Finance Mgmt Corporation has invested 0.19% in Hologic, Inc. (NASDAQ:HOLX). 9,843 are held by Bnp Paribas Asset Holding Sa.

Since August 3, 2017, it had 0 buys, and 4 sales for $1.18 million activity. ULLIAN ELAINE also sold $276,908 worth of Hologic, Inc. (NASDAQ:HOLX) on Thursday, August 3.

Analysts expect Hologic, Inc. (NASDAQ:HOLX) to report $0.49 EPS on February, 7.They anticipate $0.03 EPS change or 5.77 % from last quarter’s $0.52 EPS. HOLX’s profit would be $135.08M giving it 22.17 P/E if the $0.49 EPS is correct. After having $0.50 EPS previously, Hologic, Inc.’s analysts see -2.00 % EPS growth. The stock decreased 0.89% or $0.39 during the last trading session, reaching $43.46. About 4.36 million shares traded or 52.23% up from the average. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since January 22, 2017 and is uptrending. It has outperformed by 12.51% the S&P500.

Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage

Among 17 analysts covering Hologic (NASDAQ:HOLX), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Hologic has $5300 highest and $40 lowest target. $48.67’s average target is 11.99% above currents $43.46 stock price. Hologic had 49 analyst reports since July 24, 2015 according to SRatingsIntel. As per Thursday, August 3, the company rating was maintained by Goldman Sachs. The firm has “Overweight” rating by Piper Jaffray given on Wednesday, January 4. Argus Research maintained the shares of HOLX in report on Monday, August 3 with “Buy” rating. Canaccord Genuity maintained Hologic, Inc. (NASDAQ:HOLX) rating on Monday, September 25. Canaccord Genuity has “Buy” rating and $48.0 target. The firm has “Buy” rating by Piper Jaffray given on Monday, January 8. Deutsche Bank maintained the shares of HOLX in report on Thursday, August 3 with “Buy” rating. The rating was maintained by Needham with “Buy” on Friday, June 2. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Overweight” rating given on Wednesday, January 4 by PiperJaffray. The firm has “Buy” rating by Piper Jaffray given on Thursday, July 13. On Monday, December 11 the stock rating was upgraded by Cowen & Co to “Outperform”.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company has market cap of $11.98 billion. It operates through four divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It has a 16.46 P/E ratio. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test.

Another recent and important Hologic, Inc. (NASDAQ:HOLX) news was published by Prnewswire.com which published an article titled: “Hologic Announces Pricing of Offering of $1 Billion of Senior Notes” on January 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.